Tony Manibur Rahman1, Humphrey Julian Francis Hodgson. 1. Department of Medicine-Hepatology, Royal Free and University College Medical School, Royal Free Campus, Rowland Hill Street, Hampstead, London NW3 2PF, UK.
Abstract
BACKGROUND/AIMS: Nitric oxide (NO) is a pivotal mediator of inflammation. Its role in acute hepatic failure (AHF) is controversial. We investigated the role of NO, and the hypothesis that inhibition of inducible NO synthase (iNOS) activity would improve outcome in liver failure in rats, using the iNOS inhibitors L-NAME and aminoguanidine (AMG). METHODS: AHF was induced by two intraperitoneal injections of thioacetamide (TAA). Seven groups (n=10) were studied. Group I: TAA alone. Groups II, III and IV were additionally pre-treated with the NO precursor L-arginine (300 mg/kg i.p.), or iNOS inhibitors AMG (100 mg/kg s.c.), or N(G)-nitro-L-arginine methyl ester (L-NAME) (100 mg/kg s.c.) for 5 days, respectively. Groups V, VI and VII received L-arginine, AMG or L-NAME commencing immediately after TAA administration. Clinical and biochemical parameters were assessed serially, and mortality investigated in further similar cohorts for each regime. RESULTS: AMG, pre-treatment but not post-treatment, significantly improved outcome including mortality (10 vs. 70%, P<0.005). The less selective iNOS inhibitor L-NAME was not beneficial. Arginine pre-and post-treatment, and iNOS inhibition post-treatment, worsened clinical parameters of TAA-induced liver failure. CONCLUSIONS: Administration of the iNOS inhibitor AMG prior to insult reduces the severity of damage and improves mortality.
BACKGROUND/AIMS: Nitric oxide (NO) is a pivotal mediator of inflammation. Its role in acute hepatic failure (AHF) is controversial. We investigated the role of NO, and the hypothesis that inhibition of inducible NO synthase (iNOS) activity would improve outcome in liver failure in rats, using the iNOS inhibitors L-NAME and aminoguanidine (AMG). METHODS: AHF was induced by two intraperitoneal injections of thioacetamide (TAA). Seven groups (n=10) were studied. Group I: TAA alone. Groups II, III and IV were additionally pre-treated with the NO precursor L-arginine (300 mg/kg i.p.), or iNOS inhibitors AMG (100 mg/kg s.c.), or N(G)-nitro-L-arginine methyl ester (L-NAME) (100 mg/kg s.c.) for 5 days, respectively. Groups V, VI and VII received L-arginine, AMG or L-NAME commencing immediately after TAA administration. Clinical and biochemical parameters were assessed serially, and mortality investigated in further similar cohorts for each regime. RESULTS:AMG, pre-treatment but not post-treatment, significantly improved outcome including mortality (10 vs. 70%, P<0.005). The less selective iNOS inhibitor L-NAME was not beneficial. Arginine pre-and post-treatment, and iNOS inhibition post-treatment, worsened clinical parameters of TAA-induced liver failure. CONCLUSIONS: Administration of the iNOS inhibitor AMG prior to insult reduces the severity of damage and improves mortality.
Authors: Marek Saracyn; Marek Brytan; Robert Zdanowski; Tomasz Ząbkowski; Przemysław Dyrla; Janusz Patera; Stanisław Wojtuń; Wojciech Kozłowski; Zofia Wańkowicz Journal: World J Gastroenterol Date: 2014-12-14 Impact factor: 5.742
Authors: K V Sathyasaikumar; I Swapna; P V B Reddy; Ch R K Murthy; A Dutta Gupta; B Senthilkumaran; P Reddanna Journal: Neurochem Res Date: 2007-03 Impact factor: 3.996
Authors: Song Luo; Xiang Kong; Jin Rong Wu; Chun Yan Wang; Ying Tian; Gang Zheng; Yun Yan Su; Guang Ming Lu; Long Jiang Zhang; Gui Fen Yang Journal: Metab Brain Dis Date: 2018-07-02 Impact factor: 3.584